BARCLAYS PLC - ESPERION THERAPEUTICS INC NE ownership

ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of ESPERION THERAPEUTICS INC NE
ValueSharesWeighting
Q3 2023$87
-39.6%
88,984
-14.1%
0.00%
Q2 2023$144
-43.5%
103,648
-35.4%
0.00%
Q1 2023$255
-74.9%
160,427
-1.6%
0.00%
Q4 2022$1,017
-99.6%
163,021
+291.0%
0.00%
Q3 2022$280,000
+57.3%
41,696
+48.5%
0.00%
Q2 2022$178,000
+9.2%
28,079
-19.9%
0.00%
Q1 2022$163,000
-83.0%
35,062
-81.7%
0.00%
Q4 2021$960,000
+64.1%
191,396
+293.8%
0.00%
Q3 2021$585,000
-19.4%
48,606
+41.7%
0.00%
Q2 2021$726,000
-31.9%
34,306
-9.8%
0.00%
-100.0%
Q1 2021$1,066,000
-26.3%
38,020
-31.6%
0.00%0.0%
Q4 2020$1,446,000
+227.9%
55,625
+369.0%
0.00%
Q3 2020$441,000
-95.4%
11,861
-93.6%
0.00%
-100.0%
Q2 2020$9,502,000
+68.1%
185,193
+3.3%
0.01%
+75.0%
Q1 2020$5,653,000
-31.0%
179,308
+30.6%
0.00%
-20.0%
Q4 2019$8,188,000
+541.2%
137,313
+294.5%
0.01%
+400.0%
Q3 2019$1,277,000
-35.9%
34,807
-18.7%
0.00%0.0%
Q2 2019$1,991,000
+202.6%
42,802
+161.1%
0.00%
Q1 2019$658,000
-29.2%
16,394
-18.9%
0.00%
Q4 2018$929,000
-66.7%
20,208
-67.8%
0.00%
-100.0%
Q3 2018$2,786,000
+130.8%
62,778
+103.9%
0.00%
+100.0%
Q2 2018$1,207,000
-69.2%
30,787
-43.2%
0.00%
-66.7%
Q1 2018$3,918,000
-15.6%
54,180
-23.1%
0.00%
-25.0%
Q4 2017$4,641,000
+1127.8%
70,497
+835.1%
0.00%
Q3 2017$378,000
-94.7%
7,539
-95.1%
0.00%
-100.0%
Q2 2017$7,170,000
+827.6%
154,906
+608.1%
0.01%
+700.0%
Q1 2017$773,000
+284.6%
21,875
+35.4%
0.00%
Q4 2016$201,000
+4925.0%
16,152
+5794.9%
0.00%
Q3 2016$4,0000.0%274
-29.4%
0.00%
Q2 2016$4,000
+33.3%
388
+106.4%
0.00%
Q1 2016$3,000
-91.9%
188
-88.8%
0.00%
Q4 2015$37,000
-95.9%
1,675
-95.7%
0.00%
-100.0%
Q3 2015$904,000
-34.4%
39,383
+131.6%
0.00%0.0%
Q2 2015$1,378,000
-29.2%
17,003
-19.6%
0.00%
-50.0%
Q1 2015$1,945,000
+5302.8%
21,149
+2244.7%
0.00%
Q4 2014$36,000
-7.7%
902
-45.4%
0.00%
Q3 2014$39,000
-26.4%
1,651
-53.0%
0.00%
Q2 2014$53,000
+29.3%
3,516
+28.5%
0.00%
Q1 2014$41,000
+4000.0%
2,737
+2583.3%
0.00%
Q4 2013$1,000
-85.7%
102
-70.9%
0.00%
Q3 2013$7,0003500.00%
Other shareholders
ESPERION THERAPEUTICS INC NE shareholders Q1 2023
NameSharesValueWeighting ↓
Meditor Group Ltd 2,679,835$99,609,00022.32%
Bellevue Group AG 5,465,715$203,160,0002.81%
Rhenman & Partners Asset Management AB 455,000$16,912,0001.50%
Endurant Capital Management LP 135,901$5,051,0001.49%
Boxer Capital, LLC 975,000$36,241,0001.25%
DCF Advisers, LLC 56,500$2,100,0001.07%
Pentwater Capital Management LP 2,169,022$80,623,0001.04%
Nicholas Investment Partners, LP 235,855$8,767,0000.95%
Amia Capital LLP 20,464$761,0000.88%
HAMILTON LANE ADVISORS LLC 46,181$1,717,0000.83%
View complete list of ESPERION THERAPEUTICS INC NE shareholders